ArticleMedicine2018

The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.

Hong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.